Similar Papers

Paper Title
Journal
Date
Author
Primary refractory Hodgkin lymphoma: Limited options and poor survival—but not always
Aruna Gavini ... John L Reagan
American Journal of Hematology | VOL. 89
Aruna Gavini, et. al.Aruna Gavini ... John L Reagan
10 Apr 2014
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma
Graham P. Collins ... Anna Sureda
British Journal of Haematology | VOL. 164
Graham P. Collins, et. al.Graham P. Collins ... Anna Sureda
01 Oct 2013
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Matko Kalac ... Emily Lichtenstein
British journal of haematology | VOL. 180
Matko Kalac, et. al.Matko Kalac ... Emily Lichtenstein
16 Dec 2016
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
...
The Lancet | VOL. 385
, et. al. ...
19 Mar 2015
View more papers

More From: British Journal of Haematology

Paper Title
Journal
Date
Author
Improvement in cutaneous disease with menin inhibitor monotherapy in KMT2A rearranged AML.
John Chadwick ... Emma Searle
British journal of haematology | VOL. -
John Chadwick, et. al.John Chadwick ... Emma Searle
30 Jan 2025
T-cell-based immunotherapies for human immunodeficiency virus patient with relapsed/refractory multiple myeloma: A success story from our clinic.
S Moraru ... Laure Ricard
British journal of haematology | VOL. -
S Moraru, et. al.S Moraru ... Laure Ricard
29 Jan 2025
First relapse in older adults with multiple myeloma: Creating new pathways in uncharted territory.
Tanya M Wildes
British journal of haematology | VOL. -
Tanya M WildesTanya M Wildes
27 Jan 2025
The ITP diagnostic challenge.
Tomás José González-López
British journal of haematology | VOL. -
Tomás José González-LópezTomás José González-López
27 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.